Drug intelligence / Profile preview

cannabinoid combination

Development stage: Preclinical
Lead developer: SOL Global Investments Corp.
Modality: Small Molecules
Administration: Inhalation, Oral, Sublingual, Buccal, Topical, Intranasal, Rectal, Transdermal, Intravenous, Subcutaneous, Intraperitoneal, Ophthalmic, Pulmonary

Overview

"Cannabinoid combination" is a proprietary drug regimen developed by Scythian Biosciences in collaboration with the University of Miami. This combination drug is being investigated in pre-clinical and clinical trials with the aim of becoming the first accepted drug regimen for the treatment of concussions and neurotrauma.

Targets

PPAR (PPAR family)CNR1 (Cannabinoid receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on cannabinoid combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabinoid combination.

Explore the full profile